What percentage of men with chlamydia (Chlamydia trachomatis) develop infertility?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Chlamydia and Male Infertility: Prevalence and Impact

Approximately 3% of men with chlamydial infections develop infertility, though this estimate is based on limited evidence. 1

Epidemiology and Clinical Impact

Chlamydia trachomatis is the most common sexually transmitted bacterial infection worldwide, with an estimated 3 million new infections annually in the United States. While much attention has focused on female complications, the prevalence of infection is similar between males and females 2.

Key facts about chlamydia in men:

  • 70-90% of infections are asymptomatic 3
  • When symptomatic, typically presents as urethritis with discharge and dysuria 3
  • Can cause epididymitis, which may lead to infertility 4, 1

Pathophysiology of Male Infertility from Chlamydia

Chlamydial infection can affect male fertility through several mechanisms:

  • Direct damage to sperm, impairing parameters, increasing DNA fragmentation, and reducing acrosome reaction capacity 2
  • Infection of the testis and prostate, leading to deterioration of sperm quality 2
  • Development of epididymitis, which can cause scarring and obstruction 4

Evidence for Association with Infertility

The evidence linking chlamydia to male infertility has been more limited than for female infertility, but several important findings exist:

  • Men from couples with idiopathic infertility are significantly more likely to have antibodies to C. trachomatis at titers ≥1:64 compared to first-time expectant fathers 5
  • Higher antibody titers correlate with higher odds ratios for infertility 5
  • Past infections appear more strongly related to male infertility than current infections 6
  • The proportion of male partners in infertile couples with evidence of chlamydial infection exceeds that in the general population 2

Clinical Implications and Screening

The CDC notes that chlamydial infections among men rarely result in sequelae, though they can cause nongonococcal urethritis and acute epididymitis 4. However, the evidence suggests that the impact on male fertility may be underappreciated.

Screening considerations:

  • Annual screening is recommended for all sexually active women <25 years 4
  • Screening of sexually active young men should be considered in high-prevalence settings (adolescent clinics, correctional facilities, STD clinics) 4
  • Half of men who test positive for chlamydia antibodies have no history of genitourinary symptoms, highlighting the importance of screening beyond symptomatic cases 5

Treatment and Prevention

Effective treatment is essential to prevent complications:

  • Recommended regimens: azithromycin 1g orally in a single dose or doxycycline 100mg orally twice daily for 7 days 3
  • Treatment efficacy exceeds 95% 6
  • Partners should be treated to prevent reinfection 3
  • Abstain from sexual intercourse until both partners complete treatment 3

Conclusion

While the 3% estimate for male infertility following chlamydial infection provides a baseline figure 1, the true prevalence may be higher due to the asymptomatic nature of many infections and limited research specifically addressing male fertility outcomes. The evidence clearly demonstrates that chlamydia can impact male fertility through multiple mechanisms, and appropriate screening, diagnosis, and treatment are essential for preserving reproductive health.

References

Research

Chlamydia trachomatis: impact on human reproduction.

Human reproduction update, 1999

Guideline

Chlamydia Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.